Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

(NASDAQ:ARGX) used its fourth-quarter earnings call to highlight positive Phase 3 data in ocular myasthenia gravis (MG), continued commercial momentum for VYVGART, and its first year of annual ...

First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics ...

Argenx SE ARGX on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG). It is an autoimmune disorder where ...

Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action ...

VR headsets for gaming can improve both visual and audio experience by creating a closed environment which will make your ...

The Wild Center features indoor exhibits with turtles and otters and unique outdoor adventures across 115 Adirondack acres.

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

Roblox Corporation RBLX delivered a standout fourth quarter, with bookings surging 63% year over year to $2.2 billion, ...

Full-year product net sales rose 90% to $4.15 billion from $2.19 billion in 2024, with fourth-quarter sales reaching $1.29 ...

Canon proves that VR really can enhance your images – and now its standard Dual Pixel sensors can turn regular photos into 3D ...